Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 20/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 3/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6903749 | 1.00 | ESR1 (1.00) | ESR1ESR2PGR | |
| SCHEMBL407673 | 1.00 | ESR1 (1.00) | ESR1ESR2PGR | |
| SCHEMBL407674 | 1.00 | ESR1 (1.00) | ESR1ESR2PGR | |
| SCHEMBL5070367 | 0.94 | ESR1 (1.00) | ESR1ESR2PGR | |
| SCHEMBL28483063 | 0.94 | ESR1 (1.00) | ESR1ESR2PGR | |
| SCHEMBL5070366 | 0.94 | ESR1 (1.00) | ESR1ESR2PGR | |
| SCHEMBL21512474 | 0.94 | ESR1 (1.00) | ESR1ESR2PGR | |
| SCHEMBL5070365 | 0.94 | ESR1 (1.00) | ESR1ESR2PGR | |
| SCHEMBL1881237 | 0.93 | ESR1 (0.87) | ESR1ESR2PGR | |
| SCHEMBL1881240 | 0.93 | ESR1 (0.87) | ESR1ESR2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 639 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028309-A1 | POLYMORPHIC FORMS OF RAD1901-2HCL | RADIUS PHARMACEUTICALS INC (US) | 2026-01-29 | — | — | US | claimed |
| US-12398094-B2 | Polymorphic forms of RAD1901-2HCL | RADIUS PHARMACEUTICALS, INC. (US) | 2025-08-26 | — | — | US | claimed |
| EP-4540256-A2 | CYCLIN-DEPENDENT KINASE 2 INHIBITORS FOR MEDICAL TREATMENT | Incyclix Bio, LLC (US) | 2025-04-23 | — | — | EP | claimed |
| CN-119403808-A | Cyclin-dependent kinase 2 inhibitors for medical treatment | 因西克利克斯生物有限责任公司 | 2025-02-07 | — | — | CN | claimed |
| WO-2024220955-A2 | COMBINING INDUCTION OF FERROPTOSIS WITH TARGETED AGENTS FOR CANCER THERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-10-24 | — | — | WO | claimed |
| US-12006314-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2024-06-11 | — | — | US | claimed |
| EP-4374925-A2 | POLYMORPHIC FORMS OF RAD1901-2HCL | Radius Pharmaceuticals, Inc. (US) | 2024-05-29 | — | — | EP | claimed |
| EP-4334314-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2024-03-13 | — | — | EP | claimed |
| WO-2023249974-A2 | CYCLIN-DEPENDENT KINASE 2 INHIBITORS FOR MEDICAL TREATMENT | INCYCLIX BIO, INC. (US) | 2023-12-28 | — | — | WO | claimed |
| US-20230373904-A1 | POLYMORPHIC FORMS OF RAD1901-2HCL | RADIUS PHARMACEUTICALS, INC. | 2023-11-23 | — | — | US | claimed |
| US-6288120-B1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | PFIZER INC. | 2001-09-11 | — | — | US | claimed |
| JP-2001513525-A | — | — | 2001-09-04 | — | — | JP | claimed |
| US-6207716-B1 | FOR PROPHYLAXIS AND THERAPY OF OSTEOPOROSIS, ARTHRITIS, BREAST CANCER, CARDIOVASCULAR DISEASE | GLAXO WELLCOME INC. | 2001-03-27 | — | — | US | claimed |
| US-6124314-A | A PROSTAGLANDIN AGONISTS FOR TREATING VERTEBRATE BONE DISORDERS | PFIZER INC. (US) | 2000-09-26 | — | — | US | claimed |
| EP-1021410-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 2000-07-26 | — | — | EP | claimed |
| EP-0946501-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1999-10-06 | — | — | EP | claimed |
| EP-0911321-A2 | Compounds for the treatment of osteoporosis | PFIZER INC. (US) | 1999-04-28 | — | — | EP | claimed |
| WO-1999019300-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 1999-04-22 | — | — | WO | claimed |
| WO-1999007668-A1 | NON-STEROIDAL LIGANDS FOR THE ESTROGEN RECEPTOR | GLAXO WELLCOME INC. (US) | 1999-02-18 | — | — | WO | claimed |
| WO-1998028264-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1998-07-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12006314-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NR5A1, NCOA1, NR5A2 | ESR1 55/4885ESR2 36/4885PGR 79/4885 |
| US-20260028309-A1 | POLYMORPHIC FORMS OF RAD1901-2HCL | BRCA1, TP53, RAD1 | ESR1 16/4885ESR2 8/4885PGR 95/4885 |
| US-20230373904-A1 | POLYMORPHIC FORMS OF RAD1901-2HCL | RAD50, RAD1, RAD54L | ESR1 3662/4885ESR2 3531/4885PGR 3725/4885 |
| US-12398094-B2 | Polymorphic forms of RAD1901-2HCL | RAD50, RAD1, RAD54L | ESR1 3662/4885ESR2 3531/4885PGR 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.